Market Overview

Walgreens Is 'Poorly Positioned' In The Evolving Retail Pharmacy Space, Cowen Says

Walgreens Is 'Poorly Positioned' In The Evolving Retail Pharmacy Space, Cowen Says

Walgreens Boots Alliance Inc (NASDAQ: WBA), the newest member of the Dow Jones Industrial Average, is "poorly positioned" within the evolving retail pharmacy space, according to Cowen.

The Analyst

Charles Rhyee downgraded Walgreens Boots Alliance from Outperform to Market Perform with a price target lowered from $77 to $71.

The Thesis

The retail pharmacy space is in the early stages of transforming from a "fee-for-service" model towards "value-based care," which implies care coordination will become more important in the future, Rhyee said in a note. Walgreens' failure to fully embrace industry shifts to remain a traditional retail pharmacy would leave it more exposed to disruption.

Instead, Rhyee said CVS Health Corp (NYSE: CVS)'s proposed merger with Aetna Inc (NYSE: AET) is a prime example of a pharmacy retailer integrating care coordination in its business through the direct ownership of Aetna. This model should generate margin improvements and market share gains for CVS at the expense of Walgreens who will be reliant on generating volume at the retail level to spur growth.

It should be noted Walgreens is showing some operational problems that may be overshadowed by earnings beats, the analyst said. Since the first quarter of 2016, the company has met consensus FIFO gross margin expectations just four times and adjusted operating income expectations only six times. The multiple misses on these metrics may signal the challenging macro environment due to continuing reimbursement pressures.

Price Action

Shares of Walgreens Boots Alliance were trading marginally higher at $65.43 Monday afternoon.

Related Links:

Drug Supply Disruption: Amazon, Walmart Reportedly Vying For Online Pharmacy PillPack

Aetna Acquisition Puts CVS Growth Prospects Back In Good Health

Image credit: Mike Mozart, Flickr

Latest Ratings for WBA

Oct 2019DowngradesOverweightNeutral
Oct 2019MaintainsUnderperform
Aug 2019MaintainsEqual-Weight

View More Analyst Ratings for WBA
View the Latest Analyst Ratings

Posted-In: Charles Rhyee CowenAnalyst Color Downgrades Health Care Price Target Analyst Ratings General Best of Benzinga


Related Articles (AET + CVS)

View Comments and Join the Discussion!

Latest Ratings

NSTGStifel NicolausInitiates Coverage On28.0
MTDStifel NicolausInitiates Coverage On790.0
MITKRoth CapitalDowngrades8.0
LPTXRaymond JamesDowngrades
ILMNStifel NicolausInitiates Coverage On345.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Morgan Stanley: Newly Public Neon Therapeutics Has Outperformance Potential

Oppenheimer: Electrification Will Galvanize Delphi, Drive Outperformance